Do DIO2 rs225014 and DIO1 rs11206244 variants alter thyroid hormone activation and signaling?

Genetic variations in deiodinase enzymes introduce significant, individualized variability in thyroid hormone metabolism and tissue-level signaling.

Mechanistic pathways and cellular impacts

• DIO2 cellular stress: In intact cells, the DIO2 rs225014 (Thr92Ala) variant causes the type 2 deiodinase protein to accumulate abnormally in the trans-Golgi. This accumulation induces endoplasmic reticulum (ER) stress and impairs enzyme recycling, resulting in a 30% to 50% reduction in functional, intracellular T4-to-T3 deiodination.
• DIO1 enzyme function: The DIO1 rs11206244 (C785T) variant modulates type 1 deiodinase activity. Because DIO1 is a major enzyme responsible for peripheral T4-to-T3 conversion, this variant alters peripheral activation kinetics and impairs the clearance of reverse T3 (rT3).

Clinical and systemic consequences

• Reduced tissue-level signaling: Because DIO2 is highly expressed in target tissues like the brain, pituitary, and skeletal muscle, the rs225014-mediated impairment restricts local T3 availability. This leads to diminished tissue-level thyroid signaling and lower T3/T4 ratios, particularly in athyreotic patients or those receiving levothyroxine (LT4) monotherapy.
• Altered circulating hormone ratios: Individuals carrying the T allele of the DIO1 rs11206244 variant exhibit shifts in peripheral thyroid indices. This manifests as elevated free T4 and lower systemic FT3/FT4 and T3/rT3 ratios, indicating reduced peripheral thyroid hormone activation.

Bottom line

• The DIO2 rs225014 and DIO1 rs11206244 variants impair intracellular trafficking and enzymatic activity, respectively, directly contributing to variability in local T4-to-T3 activation and altered circulating thyroid hormone ratios.